Streetwise Expert Interviews

Anita Dushyanth

Three Biotech Investment Ideas that Disrupt and Diversify: Anita Dushyanth

Good management. Promising therapies in the pipeline. Marketed products that bolster the bottom line. Investors crave these bread-and-butter qualities in small-cap biotech and medtech companies. Anita Dushyanth of Zacks Investment Research relies on the staples, but also looks for something special, something that disrupts. In this interview with The Life Sciences Report, Dushyanth describes several small companies that have spiced up their offerings. (9/25/14) More >


Read more Streetwise Interviews. . .

including Roadmap Capital's Hugh Cleland and Stephen Ireland: Due Diligence Rules in Biotech Investment (9/17/14) More >

Newsletter Briefs

"We are very positive on TLT's technology. It's very promising." (9/25/14) Theralase Technologies Inc. - The Life Sciences Report Interview with Anita Dushyanth More >

"RP is positioned to have significant upside." (9/24/14) RepliCel Life Sciences Inc. - Douglas Ehrman, Seeking Alpha More >

"The services agreement puts AMBS on the road to commercializing LymPro." (9/23/14) Amarantus BioScience Holdings Inc. - BioTuesdays More >

"Developments with MSLP continue to reinforce its original thesis." (9/22/14) MusclePharm Corp. - Paulo Santos, Seeking Alpha More >

"BLU's confirmatory Phase 3 study has a very good probability of showing positive results." (9/17/14) BELLUS Health Inc. - The Life Sciences Report Interview with Stephen Ireland More >

"If the biotech space gets as heated as we think it will, BLU could very well trade above $10/share." (9/17/14) BELLUS Health Inc. - The Life Sciences Report Interview with Hugh Cleland More >

"IMNP's bertilimumab is a powerful antibody." (9/10/14) Immune Pharmaceuticals Inc. - The Life Sciences Report Interview with Vernon Bernardino More >

"I expect results from NBS' Phase 2 PreSERVE-AMI trial in Q4/14; that will be proof of concept for this approach." (9/10/14) NeoStem Inc. - The Life Sciences Report Interview with Vernon Bernardino More >

Expert Analysis

"Key investigators made very positive statements about CUR's NSI-566." (9/23/14) Neuralstem Inc. - Larry Smith, SmithOnStocks More >

"We reiterate our Overweight rating on THLD." (9/22/14) Threshold Pharmaceuticals Inc. - Charles Duncan, Piper Jaffray & Co. More >

"The green light for THLD's Phase 3 study of TH-302 is positive." (9/23/14) Threshold Pharmaceuticals Inc. - Andrew Fein, H.C. Wainwright & Co. More >

"CUR's NSI-566 could be a treatment capable of producing long-lasting and durable responses." (9/23/14) Neuralstem Inc. - Reni Benjamin, H.C. Wainwright & Co. More >

"We remain enthusiastic about STEM's science and clinical prospects." (9/18/14) StemCells Inc. - Stephen Dunn, LifeTech Capital More >

"We are initiating coverage on RNN with a Buy rating." (9/16/14) Rexahn Pharmaceuticals Inc. - Yale Jen, Laidlaw & Company More >

"We are initiating coverage on THLD." (9/15/14) Threshold Pharmaceuticals Inc. - Jerry Isaacson, LifeSci Advisors More >

"RXII's study data showed statistically significant improvement." (9/11/14) RXi Pharmaceuticals Corp. - Reni Benjamin, H.C. Wainwright & Co. More >